Skip to main content
Marker Therapeutics, Inc. logo

Marker Therapeutics, Inc. — Investor Relations & Filings

Ticker · MRKR ISIN · US57055L1070 US Manufacturing
Open in API
Filings indexed 899 across all filing types
Latest filing 2009-04-01 Capital/Financing Update
Country US United States of America
Listing US MRKR

About Marker Therapeutics, Inc.

https://markertherapeutics.com/

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company developing next-generation T cell-based immunotherapies for hematologic malignancies and solid tumors. The company's core technology is its Multi-Antigen Recognizing (MAR) T cell platform, which utilizes natural, non-genetically modified T cells to recognize and kill heterogeneous tumors. This approach is designed to provide durable anti-tumor responses with a favorable safety profile. Its lead product candidate, MT-601, recognizes six tumor-specific antigens and is being evaluated in a Phase 1 study for patients with lymphoma who have relapsed or are ineligible for anti-CD19 CAR-T cell therapy. The technology was originally developed at Baylor College of Medicine.

Recent filings

Filing Released Lang Actions
TAPIMMUNE8K 04/01/09
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated April 1, 2009. It details the entry into secured loan agreements, issuance of convertible debentures, warrants, and related security agreements. The content focuses on financing activities, including terms of the debentures, interest rates, warrants issuance, and related agreements. There are no financial statements or comprehensive financial performance data presented, nor is it an earnings release or annual/interim report. The primary subject is the company's capital raising and financing arrangements. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length is 4022 characters, which is sufficient to contain substantive information about the financing event rather than just an announcement or notice. Hence, the classification is CAP with high confidence.
2009-04-01 English
Regulatory Filings 2009
Regulatory Filings Classification · 95% confidence The document is a Form 12b-25 Notification of Late Filing submitted to the SEC, indicating that the company (TapImmune Inc.) could not file its Form 10-K annual report for the fiscal year ended December 31, 2008 on time. The document explains the reasons for the delay and requests an extension. It does not contain the actual annual report or financial data but is a regulatory notification about the late filing of the 10-K. The document length is 4265 characters, which is relatively short and consistent with a notification rather than a full report. According to the rules, such a notification is classified as a Regulatory Filing (RNS) because it is a compliance document related to the filing process and not the report itself.
2009-03-31 English
PRIMARY DOCUMENT
Director's Dealing
2009-03-20 English
PRIMARY DOCUMENT
Director's Dealing
2009-03-18 English
Capital/Financing Update 2009
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically discusses an increase in the company's authorized share capital, including details about the amendment and shareholder approval. This is a capital structure change announcement. The document is relatively short (2957 characters) and contains specific information about the capital increase, not just a notice or link to a report. Therefore, it fits the category of Capital/Financing Update (CAP).
2009-02-06 English
Proxy Solicitation & Information Statement 2008
Proxy Solicitation & Information Statement
2008-12-30 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.